Loading
Surrozen, Inc./DE Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by TCG Crossover GP II, LLC, was filed 25 Mar 2026.
Surrozen, Inc./DE: what insiders have been doing
Surrozen, Inc./DE is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 23 October 2026, 60 filings were filed, from 6 insiders.
On the market, 3 insiders bought (45 purchases totalling €9.4M) while 3 insiders sold (3 sales totalling €3.1M). The net balance comes to €6.3M on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €3.0M, sold by TCG Crossover GP II, LLC and made public on 24 July 2026. Among those who bought: 2 major shareholders and 1 senior executive.
Across the 3,166 companies tracked on its exchange, the median is 24 filings; at 60 filings, this issuer sits above that mark. Since 2020, the database holds 63 purchases and 10 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 3.5 m USD and net income of -242.0 m USD.
Within a 30-day window, 36 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 25 March 2026, 212 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at EssilorLuxottica and Dynavox Group AB. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
163
Thresholds
n/a
Buy Volume
€23M
63 ops. · all time
Sell Volume
€3M
10 ops. · all time
Who traded when
BuySaleColumn Group III GP, LP19 buys
TCG Crossover GP II, LLC17 buys1 sale
Tim Kutzkey12 buys
Charles O. Williams2 sales
Yang Li2 sales
Since the insiders bought
- -11.6%Entry US$28.00 · Close at T+90 US$24.75
- +62.2%Entry US$19.17 · Close at T+90 US$31.10
- +62.2%Entry US$19.17 · Close at T+90 US$31.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Surrozen, Inc./DE Strong Buy (bullish), based on 5 analysts. Average price target: US$48.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.32
Analyst consensus
5 analystsStrong buy
US$40.00Target US$48.40(+91%)US$54.00
Income statement
RevenueUS$3.5M
EBITDA-US$41.6M-1195% margin
Net income-US$242M-6960.8% margin
Valuation
PER (forward)-6.0x
Beta0.47
Balance sheet & cash
Market capUS$297.6M
Total debtUS$6.6M
Free Cash Flow-US$30.4M
Profitability & ownership
ROA-25.4%
% insiders3.1%
% institutions115.6%
Last declaration on 22 October 2026
Declarations163 total
485,830 shares@ US$11.60Common StockSEC:0001193125-26-429058:0
548,653 shares@ US$11.60Common StockSEC:0001193125-26-429058:1
517,241 shares@ US$11.60Common StockSEC:0001193125-26-429058:2
485,830 shares@ US$11.60Common StockSEC:0001193125-26-429026:0
548,653 shares@ US$11.60Common StockSEC:0001193125-26-429026:1
517,241 shares@ US$11.60Common StockSEC:0001193125-26-429026:2
162,500 shares@ US$21.2585.5% of flowCommon StockSEC:0001193125-26-316570:0
1,666 shares0Common StockSEC:0001193125-26-138292:0
53,329 shares@ US$24.693119.1% of flowCommon StockSEC:0001193125-26-124608:2
Canonical exit: 22 Jun 2026 (T+90)
7,611 shares@ US$24.89992.8% of flowCommon StockSEC:0001193125-26-124608:1
Canonical exit: 21 Jun 2026 (T+90)
7,612 shares@ US$24.89994.6% of flowCommon StockSEC:0001193125-26-124608:0
Canonical exit: 21 Jun 2026 (T+90)
17,716 shares@ US$24.87696.4% of flowCommon StockSEC:0001193125-26-108827:3
Canonical exit: 11 Jun 2026 (T+90)
17,717 shares@ US$24.87696.4% of flowCommon StockSEC:0001193125-26-108827:2
Canonical exit: 11 Jun 2026 (T+90)
595 shares@ US$24.98570.2% of flowCommon StockSEC:0001193125-26-108827:4
Canonical exit: 14 Jun 2026 (T+90)
6,187 shares@ US$24.98513.8% of flowCommon StockSEC:0001193125-26-108827:0
Canonical exit: 10 Jun 2026 (T+90)
8,881 shares@ US$23.5753.0% of flowCommon StockSEC:0001193125-26-051452:1
Canonical exit: 12 May 2026 (T+90)
547 shares@ US$23.86250.2% of flowCommon StockSEC:0001193125-26-051452:2
Canonical exit: 13 May 2026 (T+90)
546 shares@ US$23.86250.2% of flowCommon StockSEC:0001193125-26-051452:3
Canonical exit: 13 May 2026 (T+90)
8,882 shares@ US$23.5755.0% of flowCommon StockSEC:0001193125-26-051452:0
Canonical exit: 12 May 2026 (T+90)
2,135 shares@ US$21.390.6% of flowCommon StockSEC:0001193125-26-036301:1
Canonical exit: 30 Apr 2026 (T+90)
366 shares@ US$21.380.1% of flowCommon StockSEC:0001193125-26-036301:2
Canonical exit: 3 May 2026 (T+90)
365 shares@ US$21.380.1% of flowCommon StockSEC:0001193125-26-036301:3
Canonical exit: 3 May 2026 (T+90)
2,178 shares@ US$21.940.7% of flowCommon StockSEC:0001193125-26-036301:4
Canonical exit: 4 May 2026 (T+90)
2,177 shares@ US$21.940.7% of flowCommon StockSEC:0001193125-26-036301:5
Canonical exit: 4 May 2026 (T+90)
2,136 shares@ US$21.391.1% of flowCommon StockSEC:0001193125-26-036301:0
Canonical exit: 30 Apr 2026 (T+90)
25 of 163 declarations
About Surrozen, Inc./DE
Surrozen, Inc. (DE) is a US-listed biotechnology company traded on the NASDAQ Capital Market under the symbols SRZN and SRZNW. Headquartered in South San Francisco, California, the company operates in a highly specialized segment of biotech focused on selectively modulating the Wnt signaling pathway, a key biological pathway involved in tissue repair and regeneration. For French, Belgian, and Swiss investors, Surrozen is best understood as a small-cap clinical-stage biotech with a high-risk, high-upside profile that depends heavily on scientific execution and development milestones.
The company became public in 2021 through a business combination that gave it access to US capital markets. Surrozen’s platform is built around biologics and antibody-based approaches designed to selectively activate or modulate Wnt signaling in a targeted way, with the aim of addressing serious diseases where tissue repair is impaired. Its current strategic focus is centered on ophthalmology, particularly retinal and vascular eye diseases. This is an attractive therapeutic area because large unmet medical needs remain and successful therapies can generate meaningful commercial value if clinical and regulatory progress is achieved.
Read moreShow less
From a competitive standpoint, Surrozen operates in a field that includes much larger pharmaceutical and biotech companies as well as other ophthalmology and regenerative-medicine developers. Because the company does not yet have marketed products, the investment case is primarily driven by platform credibility, preclinical and clinical data, intellectual property, and the ability to secure funding. In other words, valuation is tied less to current revenue and more to the probability that one or more pipeline assets can advance successfully through development.
Recent developments point to continued momentum. In May 2026, Surrozen said it had continued advancing its lead programs in retinal vascular disease and had presented an overview of next-generation Wnt therapeutics in retinal disease at an ARVO-related event. The company also stated that it expects to submit an IND for SZN-8141 in the second half of 2026. Financially, Surrozen remains in the typical development-stage biotech category, with meaningful R&D spending and continued reliance on external capital. For investors, the stock offers exposure to a differentiated scientific platform, a NASDAQ listing in the United States, and the inherent volatility associated with clinical-stage biotechnology.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
